Salute e Benessere

Fortrea Launches AI Innovation Studio to Galvanize Technology and Human…

The studio will develop and deploy AI and machine learning (ML) technologies to drive speed, agility, quality and enhanced patient safety in the clinical research process by equipping and empowering people to focus on the critical human element of clinical trials.“Patients around the world are waiting for novel, life-changing treatments. With AI, we now have the power—and the obligation—to help deliver solutions to them faster,” said Fortrea's Chief Information Officer Alejandro Martinez...
Nasdaq GlobeNewswire
27/06/2024

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic…

SAN DIEGO and CALGARY, AB, June 27, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). The FDA supports progression-free survival as…
PR Newswire
27/06/2024

ZINZINO AB (PUBL.): ZINZINO ACQUIRES 49% OF CYPRIOT OLIVE OIL PRODUCER CLEANTHI…

The business is currently run on a small scale, with most of the production going to Zinzino's existing products R.E.V.O.O. and BalanceOil Premium. Through the partnership, Zinzino gains access to Cleanthi's IP rights, which opens up opportunities to develop and increase brand protection for Zinzino's BalanceOil, the product group that currently accounts for about 60% of the Group's total revenue. The business is currently run on a small scale, with most of the production going to Zinzino's...
PR Newswire
27/06/2024

Faucet Market to Reach $118.4 billion, Globally, by 2035 at 7.6% CAGR: Allied…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/2448 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/2448 Prime determinants of growth The faucet market is driven by increase in urbanization, population growth, and rise in residential and commercial construction activities. Rapid urbanization leads to higher demand for housing and infrastructure, resulting in a greater need for...
PR Newswire
27/06/2024

Release Therapeutics Announces New CEO to Drive Best-in-Class CNS Innovation

The appointment aligns with the company's recent strategic pivot towards treating genetic disorders of the CNS without gene therapy 1With over 25 years' experience in multinational pharma companies, including Takeda, Mundipharma International and Hoffmann-La Roche, Dr. Mehrling is an expert in developing novel oncology compounds from bench to bedside. During his tenure at MundiPharma International (2003–2013), he oversaw the clinical development, registration and launch of two major...
Nasdaq GlobeNewswire
27/06/2024

Resolution Therapeutics Receives MHRA Approval to Commence Phase I/II EMERALD…

EMERALD is an open-label, Phase I/II study which will investigate the safety and efficacy of engineered macrophage cell therapy, RTX001, in patients with decompensated liver cirrhosis. The primary analysis will focus on safety and major clinical events including death. The study will also evaluate biomarkers such as the Model for End-Stage Liver Disease (MELD) score which is used to assess disease severity and prioritise patients for a transplant. The EMERALD study will initiate in Q3 2024. ...
PR Newswire
27/06/2024

Tom Tacon appointed Business Unit Director of Bionical Virtual Engagement

At Daichi Sankyo, where he has worked since 2017, Tom spearheaded a multi-channel marketing approach – including setting up a virtual sales force, creating bespoke digital sales content and leading field sales teams. He has been involved in several highly successful UK product launches, both as a Regional Business Director (2017 – 2022) and more recently as the Brand Manager within their important cardiovascular franchise. At Daichi Sankyo, where he has worked since 2017, Tom spearheaded a...
PR Newswire
27/06/2024

Amsino Medical Group announces transformational investment from Novo Tellus

"We're excited to renew a long-term partnership with Novo Tellus" said Dr. Richard Y. Lee, Chairman and CEO of Amsino Medical Group, noting that "Novo Tellus has proven itself as a growth partner for Amsino before, and shares our fundamental commitment to delivering dependable innovation and value to our customers around the world." "We're excited to renew a long-term partnership with Novo Tellus" said Dr.Richard Y. Lee, Chairman and CEO of Amsino Medical Group…
PR Newswire
27/06/2024

Roche expands access to cervical cancer screening tools with two new WHO…

The World Health Organization (WHO) has awarded Roche's human papillomavirus (HPV) test prequalification designations for use on the cobas 5800 System and for self-collected samples on the cobas 5800, 6800 and 8800 Systems. These designations build upon last June's WHO prequalification that included the cobas HPV test for use on the cobas 6800 and 8800 Systems.WHO prequalification enables low- and middle-income countries (LMICs) to use Roche HPV screening solutions, including...
Nasdaq GlobeNewswire
27/06/2024

CARBIOS and Zhink Group enter official discussions for long-term partnership to…

This partnership would allow Zhink Group to meet its leadership ambitions through increased recycled PET capacities and sustainable competitiveness by offering recycled PET from enzymatic recyclingThis agreement confirms strong traction for CARBIOS biorecycling technology in China, the world's leading PET producerBased in China, the future plant will depolymerize minimum 50k tons of PET waste per year, with potential to expand capacities, to serve regional and global packaging and...
Nasdaq GlobeNewswire
27/06/2024

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or…

Company AnnouncementApproval based on results from Phase 1/2 EPCORE ®NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients with challenging-to-treat R/R FL EPKINLY offers an off-the-shelf, T-cell engaging treatment option that enables treatment across practice settings to address high clinical need EPKINLY is the first and only bispecific antibody approved in the U.S. to treat both relapsed or refractory (R/R) follicular lymphoma...
Nasdaq GlobeNewswire
27/06/2024

Vascular Malformations Market to Grow Substantially by 2034, Assesses…

Key Takeaways from the Vascular Malformations Market Report Key Takeaways from the Vascular Malformations Market Report Discover which therapies are expected to grab the major vascular malformations market share @Vascular Malformations Market Report Vascular Malformations Overview Vascular malformations refer to abnormalities in blood vessels that develop during embryonic or fetal development. These malformations can occur anywhere in the body and are typically present from...
PR Newswire
26/06/2024

Press Release: Dupixent positive phase 3 data in children one to 11 years of age…

Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with improvements sustained up to one yearDupixent is the first-and-only medicine indicated for eosinophilic esophagitis in the US for this age group Paris and Tarrytown, NY, June 26, 2024. The New England Journal of Medicinehas publishedresults...
Nasdaq GlobeNewswire
26/06/2024

SMISS Asia Pacific 2024 Congress and training program

Press release Ecully, June 26, 2024 – 6 p.m. Hands-on surgical training in Hong Kong at the SMISS Asia Pacific 2024 Congress The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, participated in the 4thSMISS Asia Pacificcongress, dedicated to minimally invasive surgery, held in Hong Kong on June 13 and 14. Spineway was a Bronze Sponsor of the event, where the Group presented its ESP (cervical and lumbar) prostheses through...
Nasdaq GlobeNewswire
26/06/2024

Valneva Announces Successful Outcome of its Combined General Meeting and…

Saint-Herblain (France), June 26, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Combined General Meeting (CGM) held today in Lyon, France.Among the adopted resolutions were approval of the 2023 financial statements, delegations for the management board to increase Valneva's share capital and/or issue financial instruments, and the...
Nasdaq GlobeNewswire
26/06/2024

EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for…

Press ReleaseAgreement with Sanofi on a 200 M€ investment through a Perpetual Subordinated Hybrid Bond, upon the completion of the ongoing discussions to amend and extend the current Revolving Credit Facility75 to 80 M€ annual run-rate incremental Core EBITDA targeted by the end of 2027, driven by the end of higher value API and CDMO offering, a streamlined industrial footprint, and significant cost reductions Brindisi site expected to progressively resume shipments...
Nasdaq GlobeNewswire
26/06/2024

Allergy Named Highest-Impact Journal in Allergy and Clinical Immunology for 2024

Allergy , one of EAACI's official journals, has been recognised as the highest-impact journal in the field of Allergy and Clinical Immunology for 2024. According to Journal Impact Factors released by Clarivate, Allergy boasts an impressive Impact Factor of 12.6, securing its position as the number one journal in its speciality.About Allergy Allergy is dedicated to advancing, impacting, and communicating all aspects of the discipline of Allergy and Immunology. The journal covers a...
Nasdaq GlobeNewswire
26/06/2024

Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment…

Bagsværd, Denmark, 26 June 2024– Novo Nordisk today announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK 5.7 billion related to the intangible asset ocedurenone in the second quarter of 2024. Novo Nordisk acquired ocedurenone from KBP Biosciences PTE., Ltd. in 2023. The phase 3 lead indication trial CLARION-CKD, which investigated ocedurenone in patients with uncontrolled hypertension and advanced...
Nasdaq GlobeNewswire
26/06/2024

Urinalysis Market Worth USD 6.8 Billion by 2029: Growth Drivers, Key Players…

Browse in-depth TOC on "Urinalysis Market" Browse in-depth TOC on "Urinalysis Market" 483 - Tables 49 - Figures 390 - Pages Product Segmentation in the Urinalysis Market: Consumables and Instruments The urinalysis market is segmented into consumables and instruments. Consumables, including pregnancy & fertility kits, dipsticks, reagents, and disposables, dominated the market in 2023. These products are essential for routine testing in hospitals, clinics, and labs,...
PR Newswire
26/06/2024

Blockchain Technology in Healthcare Market: Security Demand Propels Growth to…

Download a detailed overview: Download a detailed overview: https://www.skyquestt.com/sample-request/blockchain-in-healthcare-market Blockchain Technology in Healthcare Market Overview: Segments covered in Blockchain Technology in Healthcare Market are as follows: Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/blockchain-in-healthcare-market Low Costs of Public Blockchain Allow it to be Widely Used in Healthcare...
PR Newswire
26/06/2024

IVD Contract Manufacturing Services Market to be Worth $25.80 Billion by 2031 -…

IVD contract manufacturing services allow organizations to outsource manufacturing processes. Companies outsource a product or a part of a product. This is often used to increase production rates or to expand product offerings without investing in new equipment and machinery. IVD contract manufacturing services allow organizations to outsource manufacturing processes. Companies outsource a product or a part of a product. This is often used to increase production rates or to expand product...
PR Newswire
26/06/2024

HUADONG MEDICINE Announces Positive Phase I Results for Innovative Oral Small…

The Phase Ib trial of HDM1002 in China was a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-dose, escalating oral administrations of HDM1002 in overweight and obese adult subjects. Total 60 subjects were enrolled. After 28 days of continuous dosing within the dose range of 50-400mg, HDM1002 demonstrated good safety and tolerability. The most common adverse events were gastrointestinal-related, mostly mild…
PR Newswire
26/06/2024

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis, that as of June 21, BlackRock, Inc. crossed the 5% threshold regarding issued share capital in Novozymes A/S, part of Novonesis Group.Attachments 2024_24_Major_Shareholders_AnnouncementNovozymes B 21 June 2024 Final
Nasdaq GlobeNewswire
26/06/2024

Suvoda Expands its Clinical Trial Offering with the Introduction of ePatient

ePatient is set to transform the patient experience by unifying payments, appointments, reminders, and eCOA questionnaires into a single user-friendly mobile interface with the simple, intuitive design Suvoda is known for. The application's seamless integration with Suvoda's IRT and eConsent ensures a cohesive user experience, enabling site users and patients to move effortlessly between all Suvoda products with a single sign-on. ePatient is set to transform the patient experience by unifying...
PR Newswire
26/06/2024
Altri  Comunicati